Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study
William M Souza, Mariene R Amorim, Renata Sesti-Costa, Lais D Coimbra, Natalia S Brunetti, Daniel A Toledo-Teixeira, Gabriela F de Souza, Stefanie P Muraro, Pierina L Parise, Priscilla P Barbosa, Karina Bispo-Dos-Santos, Luciana S Mofatto, Camila L Simeoni, Ingra M Claro, Adriana S S Duarte, Thais M Coletti, Audrey B Zangirolami, Carolina Costa-Lima, Arilson B S P Gomes, Lucas I Buscaratti, Flavia C Sales, Vitor A Costa, Lucas A M Franco, Darlan S Candido, Oliver G Pybus, Jaqueline G de Jesus, Camila A M Silva, Mariana S Ramundo, Giulia M Ferreira, Mariana C Pinho, Leandro M Souza, Esmenia C Rocha, Pamela S Andrade, Myuki A E Crispim, Grazielle C Maktura, Erika R Manuli, Magnun N N Santos, Cecilia C Camilo, Rodrigo N Angerami, Maria L Moretti, Fernando R Spilki, Clarice W Arns, Marcelo Addas-Carvalho, Bruno D Benites, Marco A R Vinolo, Marcelo A S Mori, Nelson Gaburo, Christopher Dye, Henrique Marques-Souza, Rafael E Marques, Alessandro S Farias, Michael S Diamond, Nuno R Faria, Ester C Sabino, Fabiana Granja, Jose Luiz Proença-Módena, William M Souza, Mariene R Amorim, Renata Sesti-Costa, Lais D Coimbra, Natalia S Brunetti, Daniel A Toledo-Teixeira, Gabriela F de Souza, Stefanie P Muraro, Pierina L Parise, Priscilla P Barbosa, Karina Bispo-Dos-Santos, Luciana S Mofatto, Camila L Simeoni, Ingra M Claro, Adriana S S Duarte, Thais M Coletti, Audrey B Zangirolami, Carolina Costa-Lima, Arilson B S P Gomes, Lucas I Buscaratti, Flavia C Sales, Vitor A Costa, Lucas A M Franco, Darlan S Candido, Oliver G Pybus, Jaqueline G de Jesus, Camila A M Silva, Mariana S Ramundo, Giulia M Ferreira, Mariana C Pinho, Leandro M Souza, Esmenia C Rocha, Pamela S Andrade, Myuki A E Crispim, Grazielle C Maktura, Erika R Manuli, Magnun N N Santos, Cecilia C Camilo, Rodrigo N Angerami, Maria L Moretti, Fernando R Spilki, Clarice W Arns, Marcelo Addas-Carvalho, Bruno D Benites, Marco A R Vinolo, Marcelo A S Mori, Nelson Gaburo, Christopher Dye, Henrique Marques-Souza, Rafael E Marques, Alessandro S Farias, Michael S Diamond, Nuno R Faria, Ester C Sabino, Fabiana Granja, Jose Luiz Proença-Módena
Abstract
Background: Mutations accrued by SARS-CoV-2 lineage P.1-first detected in Brazil in early January, 2021-include amino acid changes in the receptor-binding domain of the viral spike protein that also are reported in other variants of concern, including B.1.1.7 and B.1.351. We aimed to investigate whether isolates of wild-type P.1 lineage SARS-CoV-2 can escape from neutralising antibodies generated by a polyclonal immune response.
Methods: We did an immunological study to assess the neutralising effects of antibodies on lineage P.1 and lineage B isolates of SARS-CoV-2, using plasma samples from patients previously infected with or vaccinated against SARS-CoV-2. Two specimens (P.1/28 and P.1/30) containing SARS-CoV-2 lineage P.1 (as confirmed by viral genome sequencing) were obtained from nasopharyngeal and bronchoalveolar lavage samples collected from patients in Manaus, Brazil, and compared against an isolate of SARS-CoV-2 lineage B (SARS.CoV2/SP02.2020) recovered from a patient in Brazil in February, 2020. Isolates were incubated with plasma samples from 21 blood donors who had previously had COVID-19 and from a total of 53 recipients of the chemically inactivated SARS-CoV-2 vaccine CoronaVac: 18 individuals after receipt of a single dose and an additional 20 individuals (38 in total) after receipt of two doses (collected 17-38 days after the most recent dose); and 15 individuals who received two doses during the phase 3 trial of the vaccine (collected 134-230 days after the second dose). Antibody neutralisation of P.1/28, P.1/30, and B isolates by plasma samples were compared in terms of median virus neutralisation titre (VNT50, defined as the reciprocal value of the sample dilution that showed 50% protection against cytopathic effects).
Findings: In terms of VNT50, plasma from individuals previously infected with SARS-CoV-2 had an 8·6 times lower neutralising capacity against the P.1 isolates (median VNT50 30 [IQR <20-45] for P.1/28 and 30 [<20-40] for P.1/30) than against the lineage B isolate (260 [160-400]), with a binominal model showing significant reductions in lineage P.1 isolates compared with the lineage B isolate (p≤0·0001). Efficient neutralisation of P.1 isolates was not seen with plasma samples collected from individuals vaccinated with a first dose of CoronaVac 20-23 days earlier (VNT50s below the limit of detection [<20] for most plasma samples), a second dose 17-38 days earlier (median VNT50 24 [IQR <20-25] for P.1/28 and 28 [<20-25] for P.1/30), or a second dose 134-260 days earlier (all VNT50s below limit of detection). Median VNT50s against the lineage B isolate were 20 (IQR 20-30) after a first dose of CoronaVac 20-23 days earlier, 75 (<20-263) after a second dose 17-38 days earlier, and 20 (<20-30) after a second dose 134-260 days earlier. In plasma collected 17-38 days after a second dose of CoronaVac, neutralising capacity against both P.1 isolates was significantly decreased (p=0·0051 for P.1/28 and p=0·0336 for P.1/30) compared with that against the lineage B isolate. All data were corroborated by results obtained through plaque reduction neutralisation tests.
Interpretation: SARS-CoV-2 lineage P.1 might escape neutralisation by antibodies generated in response to polyclonal stimulation against previously circulating variants of SARS-CoV-2. Continuous genomic surveillance of SARS-CoV-2 combined with antibody neutralisation assays could help to guide national immunisation programmes.
Funding: São Paulo Research Foundation, Brazilian Ministry of Science, Technology and Innovation and Funding Authority for Studies, Medical Research Council, National Council for Scientific and Technological Development, National Institutes of Health.
Translation: For the Portuguese translation of the abstract see Supplementary Materials section.
Conflict of interest statement
MSD is a consultant for Inbios, Vir Biotechnology, NGM Biopharmaceuticals, and Carnival Corporation, and on the Scientific Advisory Boards of Moderna and Immunome. MSD is the principal investigator of a laboratory that has received funding support in sponsored research agreements from Moderna, Vir Biotechnology, and Emergent BioSolutions.
© 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license.
Figures
References
- Wu F, Zhao S, Yu B. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265–269.
- WHO WHO coronavirus (COVID-19) dashboard.
- Rambaut A, Holmes EC, O'Toole Á. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat Microbiol. 2020;5:1403–1407.
- Hou YJ, Chiba S, Halfmann P. SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. Science. 2020;370:1464–1468.
- Chi X, Yan R, Zhang J. A neutralizing human antibody binds to the N-terminal domain of the spike protein of SARS-CoV-2. Science. 2020;369:650–655.
- Piccoli L, Park YJ, Tortorici MA. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. Cell. 2020;183:1024. 42.e21.
- Thomson EC, Rosen LE, Shepherd JG. Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. Cell. 2021;184:1171. 87.e20.
- Wang Z, Schmidt F, Weisblum Y. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 2021;592:616–622.
- Tegally H, Wilkinson E, Giovanetti M. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature. 2021;592:438–443.
- Davies NG, Abbott S, Barnard RC. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021;372
- Garcia-Beltran WF, Lam EC, St Denis K. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021;184:2372. 83.e9.
- Dejnirattisai W, Zhou D, Supasa P. Antibody evasion by the P.1 strain of SARS-CoV-2. Cell. 2021 doi: 10.1016/j.cell.2021.03.055. published online March 30.
- Chen RE, Zhang X, Case JB. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat Med. 2021;27:717–726.
- Faria NR, Mellan TA, Whittaker C. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science. 2021;372:815–821.
- Zhang Y, Zeng G, Pan H. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21:181–192.
- Wölfel R, Corman VM, Guggemos W. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581:465–469.
- Corman VM, Landt O, Kaiser M. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25
- Davanzo GG, Codo AC, Brunetti NS. SARS-CoV-2 uses CD4 to infect T helper lymphocytes. medRxiv. 2020 doi: 10.1101/2020.09.25.20200329. published online Sept 28. (preprint).
- Perera RA, Mok CK, Tsang OT. Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020. Euro Surveill. 2020;25
- Araujo DB, Machado RRG, Amgarten DE. SARS-CoV-2 isolation from the first reported patients in Brazil and establishment of a coordinated task network. Mem Inst Oswaldo Cruz. 2020;115
- Naveca F, da Costa C, Nascimento V. SARS-CoV-2 reinfection by the new variant of concern (VOC) P.1 in Amazonas, Brazil.
- Buss LF, Prete CA, Jr, Abrahim CMM. Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic. Science. 2021;371:288–292.
- Hoffmann M, Arora P, Groß R. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell. 2021;184:2384. 93.e12.
- Bueno SM, Abarca K, González PA. Interim report: safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy Chilean adults in a phase 3 clinical trial. medRxiv. 2021 doi: 10.1101/2021.03.31.21254494. published online April 1. (preprint).
- Palacios R, Batista AP, Albuquerque CSN. Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: the PROFISCOV study. SSRN. 2021 doi: 10.2139/ssrn.3822780. published online April 14. (preprint).
- Smith DJ, Lapedes AS, de Jong JC. Mapping the antigenic and genetic evolution of influenza virus. Science. 2004;305:371–376.
- Eguia RT, Crawford KHD, Stevens-Ayers T. A human coronavirus evolves antigenically to escape antibody immunity. PLoS Pathog. 2021;17
- Röltgen K, Powell AE, Wirz OF. Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome. Sci Immunol. 2020;5
- Lucas C, Klein J, Sundaram ME. Delayed production of neutralizing antibodies correlates with fatal COVID-19. Nat Med. 2021 doi: 10.1038/s41591-021-01355-0. published online May 5.
Source: PubMed